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Cocoa-related products like chocolate have taken an important place in our food habits 
and culture. Preliminary research data shows that theobromine, a methylxanthine 
present in high concentrations in cocoa, might have a protective effect against 
Alzheimer’s Disease (AD). In this work, we aim to examine the relationship between 
chocolate consumption and cognitive decline in an elderly cognitively healthy 
population. Furthermore, we will discuss the current state of the art concerning the 
study of the cognitive effects of chocolate and theobromine. A cohort of 531 
participants aged 65 and over with a Mini-Mental State Examination (MMSE) not 
compatible with cognitive impairment was selected for the present study. The median 
follow-up was 48 months. Dietary habits were evaluated at baseline. The MMSE was 
used to assess global cognitive function at baseline and at follow-up.  Cognitive decline 
was defined by a decrease ≥ 2 points in the MMSE score between evaluations. Relative 
risk (RR) and 95% confidence interval (95%CI) estimates were adjusted for age, 
education, smoking, alcohol drinking, body mass index, hypertension, and diabetes. 
Chocolate intake was associated with a lower risk of cognitive decline (RR = 0.59, 
95%CI 0.38 – 0.92). To our knowledge, this is the first study to have assessed the 
negative association between regular long-term chocolate consumption and cognitive 
decline in humans. 
 










Os produtos com conteúdo de cacau, tais como o chocolate, conquistaram um 
importante lugar nos nossos hábitos alimentares e na nossa cultura. Dados preliminares 
indicam que a teobromina, uma metilxantina presente em alta concentração nos 
produtos à base de cacau, pode apresentar efeitos protectores contra o desenvolvimento 
da Doença de Alzheimer. Ao longo deste trabalho, iremos examinar a relação entre o 
consumo de chocolate e o surgimento de declínio cognitivo numa população 
envelhecida e cognitivamente saudável. Adicionalmente, iremos discutir o estudo dos 
efeitos cognitivos do chocolate e da teobromina. Para este estudo, foi selecionado uma 
coorte de 531 participantes com idade igual ou superior a 65 anos e com um valor no 
Mini-Mental State Examination (MMSE) incompatível com défice cognitivo. O período 
médio de seguimento foi de 48 meses. Os hábitos dietéticos foram avaliadas na linha de 
base. O MMSE foi utilizado para avaliar o funcionamento cognitivo geral tanto na linha 
de base como após o seguimento. Para se afimar a existência de de declínio cognitivo, 
um indivíduo teria que ter um decréscimo de ≥ 2 pontos no MMSE entre as avaliações. 
As estimativas do Risco Relativo (RR) e do intervalo de confiança de 95% (95%IC) 
foram ajustadas para a idade, educação, hábitos tabágicos, consumo de álcool, índice de 
massa corporal, hipertensão e diabetes. O consumo de chocolate foi associado a um 
menor risco de declínio cognitivo (RR = 0.59, 95%IC 0.38 – 0.92). De acordo com a 
nossa pesquisa, este é o primeiro estudo a avaliar a associação negativa entre o consumo 
regular e prolongado de chocolate e o surgimento de declínio cognitivo em humanos. 
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Chocolate consumption is generally considered a healthy and pleasant 
widespread habit. Despite the drawbacks related to the high caloric intake associated 
with this practice, its numerous beneficial effects on different main systems in the 
human physiology have been largely studied (1,2). In fact, many of the potential 
advantages of chocolate consuming have been attributed to the antioxidative properties 
of its components, namely the polyphenolic structures named flavonols (3). 
Remarkably, a new insight to what might be in the source of such benefits has been 
proposed in the past few years, with special regard to the psychoactive and 
neuroprotective effects of the methylxanthines present in chocolate and their implication 
in the prevention of neurodegenerative diseases (1,4,5).  
Caffeine and theobromine are two similar methylxanthines present in chocolate, 
coffee and tea. Whereas caffeine is the most abundant methylxanthine in coffee, 
theobromine has been found to be the main xanthine in all types of chocolate (4,6). The 
combination of caffeine and theobromine in the proportions found in cacao (the main 
compound of chocolate) has been shown to display psycho-stimulant effects (7,8). 
Besides, there is increasing evidence that dietary methylxanthines, such as those 
commonly found in chocolate products, may possess neuroprotective effects and are 
associated with significantly improved and/or preserved aspects of cognitive 
functioning (5). Caffeine, in particular, has been widely explored, in terms of its 
preventive effect on the development of two of the most prevalent neurodegenerative 
diseases, such as Parkinson’s (9) and Alzheimer’s Disease (AD) (10). Notably, a recent 
systematic review and meta-analysis of 11 observational epidemiological studies has 
pointed for a protective effect of chronical exposure to caffeine against dementia, AD, 
cognitive impairment and cognitive decline (11). However, the effects of theobromine 
have been less studied than those of caffeine (1,4,5), and the potential neuroprotective 
effect of theobromine is still poorly understood (6).  
Despite their various mechanisms of action, both molecules seem to act mainly 
as nonspecific antagonists of adenosine receptors when considering a normal degree of 
consumption (1,4). In fact, the administration of adenosine A2A receptor antagonists has 
been proven to prevent memory deficits in different animal AD models (12,13). In 
addition, both the blockade of A2A receptors has also been shown to reduce the 
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production of amyloid-β, a peptide that accumulates in the brain of AD patients, and 
limit its synaptotoxic effect (13,14).  
In the past years, biomarkers for AD diagnosis and early-detection have been 
intensively studied and the concentration of Aβ42 in the cerebrospinal has been found to 
be reduced in AD patients with different stages of the disease (15). Remarkably, the 
BIOMARKAPD project recently showed a significant positive correlation between the 
concentrations of theobromine in the cerebrospinal fluid and in the plasma with 
amyloid-β in the cerebrospinal fluid, suggesting that theobromine might also have a 
protective effect against AD (16). 
                   
Fig. 1) Chemical structure of caffeine, theobromine and adenosine. Adapted from (1). 
 
 
Animal studies on the cognitive effect of chocolate/cocoa  
To date, there are only two published studies that address the effect of cocoa-
related products on animal’s cognitive function.  
In 2007, Rozan et al. investigated the short-term effect of a cocoa polyphenolic 
extract (Acticoa powder) on free radicals produced by leucocytes after heat exposure 
and the extract’s protective effects on subsequent cognitive impairments. The authors 
concluded that the 14-days oral administration of Acticoa powder had protected heat-
exposed rats from cognitive impairments (by better performances in light extinction and 
Morris maze paradigms, meaning preserved short and long-term memory processes), 
potentially by counteracting the overproduction of free radicals and suggested that the 
cognitive outcomes could be related to preservation of brain function as a result of 
reduced inflammatory aggression, heat exposure, or enhanced brain plasticity (17).  
Short after in 2008, Bisson et al. addressed the long-term effect on cognitive 
functions of the same polyphenolic extract, Acticoa powder, in old Wister-Unilever rats. 
During 12 months, they orally received supplementation at the dose 24 mg/kg/day, and 
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were also evaluated through light extinction and the Morris water maze, showing 
improved cognitive performance in terms of spatial memory and short- and long- term 
learning, increased lifespan by around 11% and preserved high urinary free dopamine 
levels, a neurotransmitter associated with important cognitive functions, such as 
efficient memory and problem-solving. In this light, the authors suggested that Acticoa 
powder could be beneficial in retarding age-related brain impairments, including 
cognitive deficits in normal ageing and perhaps neurodegenerative diseases (18). 
 
 
Human studies on the cognitive effect of chocolate/cocoa 
There is a wide range of data demonstrating beneficial cognitive effects of 
chocolate, cocoa and some of its components (1–6,19–22).  
Despite not being focused solely on chocolate but also on the consumption of tea 
and coffee, a cross-sectional study involving 2031 subjects (aged 70-74 years) by Nurk 
et al. in 2009, based on the food habits reported in the previous year, concluded that 
habitual chocolate consumers had performed better in all cognitive tests applied and that 
the risk for poor test performance in most tests had been significantly reduced by 
chocolate consumption (23). The large population and the use of six different cognitive 
tests (including the MMSE) were major strengths of this study, but it is noteworthy to 
refer that the authors acknowledged some weaknesses, such as the study’s retrospective 
cross-sectional design, the potential error in the estimates of nutrients and the volunteer 
sample, which might have been a source of recruitment bias.  
In 2010 Scholey and colleges designed a randomized, double-blind, controlled 
trial to examine the acute cognitive and subjective effects of cocoa flavanols 
consumption. In this study, 30 healthy young adults consumed high-flavanol cocoa 
drinks and a matched control drink. Over a 1 h testing period, participants repeatedly 
performed 10-min cycles of a Cognitive Demand Battery, a Rapid Visual Information 
Processing (RVIP) task, and a “mental fatigue” scale. Among other findings, the 994-
mg beverage yielded speeded RVIP responses and the 520-mg beverage attenuated self-
reported “mental fatigue”. This was the first report on immediate improvements of 




In a recent systematic review by Scholey et al. published in 2013, of the eight 
studies that met the criteria for inclusion, three revealed clear evidence of cognitive 
enhancement following cocoa flavanols and methylxanthine consumption (19). All 
studies examined the cognitive effects of potentially psychoactive fractions of 
chocolate: five studies focused on cocoa flavonol fractions of cocoa (22,24–27) and 
three (from two articles) on combinations of the methylxanthines: caffeine and 
theobromine (7,28). In summary, this review concluded that there is a growing body of 
evidence indicating improved cognitive function with acute administration of cocoa 
flavonols, caffeine and theobromine, in isolation and in combination. It also stated that, 
despite seemingly strong evidence from epidemiological studies (23), no study had yet 
found cognitive effects in randomized controlled trials using sub-acute or chronic 
administration of chocolate and its components in humans. The dosing regimens periods 
varied from 5 days to 6 weeks and it was hypothesized that the lack of positive 
outcomes was related to possible methodological aspects (19).  For example, in 2008 
Crews et al. published an article concerning a double-blind, placebo-controlled, fixed-
dose, parallel group clinical trial in which 101 healthy subjects were randomly assigned 
to receive a 37-g dark chocolate bar and 237 mL of an artificially sweetened cocoa 
beverage or similar placebo products each day for 6 weeks. The results failed to support 
the predicted sub-acute enhancing effects of dark chocolate and cocoa consumption on 
neuropsychological status. Again, the authors stated that there were recognized 
difficulties that could have contributed to the negative findings, such as the apparent 
cognitive intact profile and educational level (>15 years) of the subjects at baseline, the 
small sample size which may not have been large enough to detect significant group 
differences and the short duration of the treatment or the low quantity of 
chocolate/cocoa administered to subjects (26).  
Probably because the electronic databases were searched in early-2012 for the 
review of Scholey et al. (19), a later article by Desideri and collaborators published in 
mid-2012 was not addressed. Included in the Cocoa, Cognition, and Aging (CoCoA) 
Study, this  double-blind, parallel arm study in which 90 elderly individuals were set to 
consume cocoa drinks once daily for 8 weeks provided the first evidence that regular 
cocoa flavanol consumption could positively enhance cognitive function in older adults 
with mild cognitive impairment (29).  
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More recently, two randomized controlled trials revealed contradictory results 
concerning the effect of cocoa on cognitive function. Published in 2015 and also based 
on the Cocoa, Cognition, and Aging (CoCoA) Study, one of these randomized 
controlled trials found that daily cocoa consumption for 8 weeks had improved specific 
aspects of cognitive performance in a group of cognitively intact older adults (30). As in 
other studies, it was focused on the flavonoid content of cocoa, but it is interesting to 
notice that the results on the MMSE did not differ between the low and high-flavonoid 
intake groups and that even the low-flavonoid intake group had a significant 
improvement on the Verbal Fluency Test. As the authors hypothesize, given this drink’s 
very low amount of flavonoids, it is possible that this improvement might have been 
attributed to the effect of the methylxanthines present in the ingested products (30). The 
second study, also published in 2015, was a randomized, placebo-controlled, double-
blind clinical trial comprising 40 subjects, conducted to investigate the effects of both 
acute and sub-acute (four-weeks) 3058 mg Theobroma cacao seed extract daily 
supplementation on mood and mental fatigue, cognitive performance and cardiovascular 
functioning in young, healthy adults (31). Similarly to Crews et al. study of 2008 (26), 
supplementation with cocoa extract did not result in significant sub-acute positive 
effects.  
In spite of these negative results, it is still possible that the long-term cumulative 
supplementation or regular ingestion of cocoa or chocolate may result in cognitive 
protection or enhancement. Along with the present work, more studies regarding the 




Studies on the cognitive effect of caffeine and/or theobromine  
Studies that address the effect of caffeine on cognitive function are abundant, 
both in animals (32) and in humans. Not only are there studies focused on the short-term 
effect of this methylxanthine (33,34), there are also various studies and reviews on the 
long-term effects of caffeine (11,14,35–37).  
In 2007, Chen and collaborators published a review in which they highlighted 
A2A receptors ability to fine tune neuronal and glial functions to produce 
neuroprotective effects. Modulation of A2A receptors could facilitate the 
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neurophysiological mechanisms of learning and memory, by interfering with the 
pathological changes of AD or strengthening the resistance of neuronal cells to insults. 
This effect has been proposed to decrease the probability of emergence of AD in healthy 
subjects, or attenuate the disease progression in patients already affected (38). In fact, 
plasma and brain amyloid-β levels have been found to be reduced by acute or chronic 
caffeine administration in several AD transgenic lines and ages (33).  
However and to our knowledge, there are still no randomized controlled trials on 
humans that address the long-term effect of theobromine on cognition and there are only 
a very few early publications to have reported individual and combined effects of 
caffeine and theobromine (6). In fact, theobromine has been generally ignored, partially 
due to the prevalent idea that it is a very low central nervous system stimulant (39,40).  
Apart from some evidence provided by Ott in 1985 (considered to be 
“anecdotal” by Smit et al. (6)) who replaced his dietary caffeine intake with a daily dose 
of 600 mg theobromine and documented a similar behavior to caffeine in terms of its 
capacity to produce withdrawal symptoms, theobromine has only been showed to 
produce very minor subjective effects compared with caffeine (41).  
A study by Smit and collaborators (2004) showed that both cocoa powder and a 
methylxanthine mixture containing a combination of caffeine and theobromine had 
significant similar effects on reaction time, energetic arousal and information 
processing. They concluded that the psychostimulant effect of chocolate is mainly due 
to the methylxanthines present in chocolate (7), an allegation that was considered to be 
“premature” in the review by Scholey et al., knowing of the demonstrable acute 
psychoactive effects of other components of chocolate, such as cocoa flavonols (19).  
Nonetheless, one possible explanation on the different effects of caffeine and 





Pharmacokinetics and pharmacodynamics of caffeine and theobromine  




Theobromine absorption from the digestive tract is slow, with an estimated peak 
plasma time of 2.5 h (compared with 0.5 h for caffeine) (42). The clearance rate for 
acutely administered theobromine is 1.2 ml/min/kg, around half of that of caffeine (2.1 
ml/min/kg). This contributes to a higher half-life for theobromine compared to caffeine 
(7.2 h against 4.1 h) (45). It has also been stated that inter-individual differences in 
theobromine clearance rates may be substantial, as is the case for caffeine (46). 
Additionally, it is important to be aware of the different conditions that may alter the 
clearance rate of these compounds, either by its decrease or enhancement (i.e. tobacco-
smoking habits (47,48)).  
 
 Caffeine Theobromine 
Peak plasma time 
(t max) 
0.5 h 2.5 h 
Clearance rate 2.1 ml/min/kg 1.2 ml/min/kg 
Half-life 4.1 h 7.2 h 
 
Table 1) Pharmacokinetic profiles of caffeine and theobromine. Adapted from (42,45). 
 
 
In humans, methylxanthines are metabolized by demethylation by the enzyme 
superfamily cytochrome P450, especially its member CYP1A2 which is responsible for 
more than 95% of the primary metabolism of caffeine, making caffeine an important 
probe drug to monitor this enzyme’s activity (49). Caffeine is metabolized to different 
compounds, including theobromine. Theobromine does not metabolize into other 
dimethylxanthines (i.e. theophylline or paraxanthine), nor does it “upgrade” to the 
trimethylxanthine caffeine. Because of this, the consumption of cocoa-related products 
exposes humans both to theobromine from the demethylation of caffeine, in addition to 
the direct ingestion of theobromine contained in these products (6).  
Regarding the pharmacodynamic profile of the different methylxanthines, these 
have been show to display different affinities for the different receptor types (6). While 
theobromine is only 2- to 3-fold less active than caffeine as an antagonist of the 
adenosine A1 receptors in rat brain, it is at least 10-fold less active than caffeine as an 
antagonist of A2A receptors (50). Similar results were documented by Fredholm and 
Lindström in 1999, but these authors also provided evidence on the different caffeine-
to-theobromine affinity ratios measured for striatum compared with cortex A1 receptor 
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antagonism (theobromine was found to be 4.7 and 11.8 times less active than caffeine, 
respectively). With this work, the authors concluded that neither of the methylxanthines 
studied had showed any selectivity for a specific type of adenosine receptor (51). 
Finally it is also important to acknowledge that theobromine penetrates the brain to a 
lesser extent than caffeine (39). 
 
 
 A2A Striatum A1 Striatum A1 Cortex 
Caffeine 8,556 (6,468-11,312) 20,490 (11,809-34,837) 16,643 (9,871-27,962) 
Theobromine 109,048 (19,483-577,561) 196,505 (66,964-158,474) 197,000 (167,600-234,300) 
 
Table 2) Potency of caffeine and theobromine to displace CGS 21680 (adenosine receptor agonist) from 
adenosine receptors. Results are given as Ki values in nM (mean and 95% confidence interval). Adapted 
from (51). 
 
These different affinities for different receptor types may then explain the 
alternative effects of caffeine and theobromine. 
Given all this evidence, the role theobromine on chocolate consumption 
cognitive effects seems to be rather limited. However, the identification of potential risk 
and protective factors, such as the consumption of theobromine-enriched products like 
chocolate, should be targeted as vital for the prevention of neurodegenerative disorders. 
 
Main goal 
In this present study we aim to assess the association between chocolate 
consumption and cognitive decline. The hypothesis that chocolate could decrease the 
incidence of cognitive decline by at least 2 points in the score of a widely used cognitive 
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 This work is based on the data already collected for a wider research, the EPIPorto study. My 
personal contribution focused on the aspects mentioned above and was adapted to match the 





This study was based on the evaluation of a cohort of adults living in Porto, as 
previously described (36). Briefly, a total of 2485 participants were recruited between 
1999 and 2003, by random digit dialling having households as the sampling unit; when 
a household was selected, all residents were identified by age and gender, and one 
resident (aged 18 or more years) was randomly selected as the respondent, without 
replacement if there was a refusal. The participation rate was 70%. A visit to the 
Department of Clinical Epidemiology, Predictive Medicine and Public Health of Porto 
Medical School (former Department of Hygiene and Epidemiology of Porto Medical 
School) was scheduled by telephone according to the participant’s convenience. A 
personal interview, using a structured questionnaire comprising data on socio-
demographic, clinical, and lifestyle exposures, and a physical examination was 
performed by trained interviewers. From the whole cohort, 648 participants were aged 
65 and over and 531 were selected for the present study, after exclusion of 62 
cognitively impaired at baseline (the criteria used to define cognitive impairment is 
defined below), 32 for whom there was no baseline MMSE, and 23 for whom there was 
no information on chocolate or caffeine intake. 
 
Follow-up evaluation 
The follow-up evaluation of the cohort took place between 2005 and 2008. A 
visit to the Porto Medical School was scheduled, for questionnaire evaluation and 
physical examination of the participants. 
 
Cognitive testing 
The MMSE (52,53) was used to assess global cognitive function at baseline and 
at follow-up. The MMSE, which includes questions on orientation, registration, 
attention and calculation, recall, language and visual construction, was originally 
designed for clinical practice, but is now extensively used in epidemiological studies. 
Although it does not assess executive function, a major feature of cognitive decline 
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(52), the MMSE is a reliable and valid test for cognitive impairment, has high test-retest 
reliability, and is a good indicator of clinically significant cognitive decline (54). The 
cut-off values adjusted for education levels were used as proposed in other studies 
(55,56). The normative cut-off values of MMSE adjusted for education for the 
Portuguese population were used (53). Subjects that had a MMSE score below cutoff at 
baseline were considered to be cognitively impaired and therefore excluded. 
Participants had to score above 15 if they were illiterate, above 22 if they had ≤ 11 years 
of education, and above 27 if they had > 11 years of education. 
A decline of at least 2 points in the score of the MMSE from baseline to the 
follow-up visit was considered meaningful from a clinical point of view (35). 
 
Chocolate dietary intake 
Dietary habits in the 12 months preceding the baseline interview were evaluated 
using a semi-quantitative food frequency questionnaire (FFQ) comprising 82 food and 
beverage items or groups. It was designed according to Willett et al. (57), and was 
adapted by inclusion of a variety of typical Portuguese food items and validated as 
previously described. For each FFQ item, subjects were asked the average frequency of 
consumption and the portion size usually consumed (based on a photograph manual 
with small, medium and large portion sizes). This information was used to estimate the 
average daily intake of each item by multiplying the usual frequency of intake per day 
by the average portion size of the corresponding item. The food items/groups of the 
FFQ used to address chocolate overall consumption were chocolate bars, chocolate 
snacks and cocoa powder. 
 
Socio-demographic, clinical and other behavioural factors 
The assessment of socio-demographic, clinical and other behavioural factors was 






Data analysis was conducted in 309 subjects who at baseline were aged 65 or 
more and had a MMSE not compatible with cognitive impairment, and who were re-
evaluated. Comparison of the baseline characteristics between subjects that were 
followed, died or were lost to follow up was done using the Chi-Square or the Kruskal-
Wallis tests, as appropriate, to compare all groups. 
The association between chocolate intake and the development of cognitive 
impairment was quantified through crude and age-, education-, body mass index, 
diabetes-, hypertension-, smoking- and alcohol drinking-adjusted relative risks (RR) and 
respective 95% confidence intervals (95%CI) using Poisson regression. Data were 
analysed using STATA
®
, version 11. 
Decline in cognitive performance was defined as a decrease of at least two 
points on the MMSE from the baseline assessment to follow up and impairment in 
cognitive performance was defined based on normative cut-off values of MMSE 
adjusted for education for the Portuguese population. 
 
Ethics 
This study was approved by a local Ethics Committee, and all participants gave 






Among the 531 participants that were eligible, 309 (58.2%) completed the 
follow-up evaluation (median follow-up: 48 months), 58 (10.9%) died before follow-up 
could be accomplished and there were 164 (30.9%) losses to follow-up. Participants 
who died during the follow up period were more likely to be older, hypertensive, to 
have a lower BMI, and worse MMSE score. No statistically significant differences 
between the groups were found regarding education, smoking, alcohol, diabetes and 
caffeine or chocolate consumption (Table 3). 
Chocolate intake was independently associated with a nearly 40% lower risk of 
cognitive decline, defined as ΔMMSE≤-2 between baseline and follow-up. The RR 
estimates were similar for the different levels of chocolate consumption analysed, 
though only statistically significant for participants with an average weekly 
consumption of chocolate lower than one standard portion, corresponding to three 
pieces of chocolate bar, one chocolate snack or one table spoon of cocoa powder (Table 
4). Chocolate intake was not significantly associated with a decreased risk of cognitive 


















Sex (% women) 58.6 44.8 63.4 0.047 
Age (years)* 70 (67-74) 74 (69-79) 72.5 (69-76) <0.001 
Age (% ≥75 years) 20.71 46.55 34.76 <0.001 
Education (years)
* 
4 (4-8) 4 (4-7) 4 (3-7) 0.3459 
Education (%)  
      Illiterate 
     <12 years 



















 27.8 (25.0-29.9) 26.2 (22.4-30.1) 27.5 (24.7-30.7) 0.1651 
Body mass index (%) 
     ≤25.0 Kg/m
2
 
     25.0-29.9 Kg/m
2
 

















Smoking (% ever smokers) 34.0 43.1 26.2 0.055 
Alcohol drinking (% ever drinkers) 86.1 82.8 85.9 0.796 
Hypertension (%) 79.7 90.7 90.5 0.004 
Diabetes (%) 12.0 17.5 13.4 0.515 
MMSE* 28 (27-29) 28 (25-29) 27.5 (25.5-29) 0.008 
Caffeine intake (mg/day)* 32.8 (10.6-78.8) 33.9 (13.9-78.9) 32.1 (13.6-78.8) 0.840 
Chocolate intake (% consumers) 40.1 41.4 39.6 0.973 
 




Table 4) Association between chocolate consumption and cognitive decline (ΔMMSE≤ -2) or development of cognitive impairment*. 
  Δ MMSE≤ -2  Cognitive impairment* 
 





 Crude Adjusted 
a
  PM 
No. subjects 
with outcome 





     No 
 







































Chocolate intake  
     
     No intake 
 
     ˂ 1 portion† / week 
 































































RR – Relative risk; 95% CI – 95% Confidence interval; PM – Person months; MMSE – Mini-Mental State Examination;  – MMSE at follow-up - MMSE at baseline. 
* The normative cut-off values of MMSE adjusted to the education for the Portuguese population were used. Subjects were classified as cognitively impaired at follow-up when having a MMSE 
score below 16 if they were illiterate, 23 if they had ≤ 11 years of education, 28 if they had > 11 years of education. 
a adjusted for age (continuous), education (continuous), body mass index – BMI (continuous), diabetes, hypertension, smoking (never/ever), and alcohol drinking (never/ever). Hypertension, 
diabetes, IMC, tobacco and alcohol consumption were assessed as previously described (36). Arterial hypertension was defined as systolic blood pressure ≥140 mmHg and/or diastolic blood 
pressure ≥90 mmHg and/or current antihypertensive drug therapy (58). Participants on anti-diabetic therapy and/or with fasting plasma glucose concentrations ≥126 mg/dL and/or diagnosed with 
diabetes by a health professional were considered to have diabetes mellitus (59). Body mass index (BMI) was calculated as weight (kg) divided by squared height (m2), and further divided into 
the following categories (60): obese (≥30 kg/m2), overweight (25.0–29.9 kg/m2), normal and underweight (<24.9 kg/m2). Regarding smoking habits and the consumption of alcoholic beverages, 
subjects were categorized in never- and ever-smokers and never- and ever-drinkers.  




Our results suggest that the consumption of chocolate has a protective effect on 
cognitive decline in elderly patients, as defined by the decrease in two or more points in 
the MMSE.  
To the best of our knowledge, no other observational studies have specifically 
addressed the long-term effect of chocolate consumption on cognitive decline in 
humans. As stated before, most studies are generally focused on the intake of 
antioxidant and flavonoid compounds present in chocolate or cocoa, rather than 
chocolate intake itself or its methylxanthine content (21,23,61–63), making it hard to 
establish direct relations between this and other studies. Furthermore, most studies deal 
with the acute  (22,24,27,31) and sub-acute (26,30,31) cognitive enhancing effects of 
both flavonoids and methylxanthines and not the potential protective chronic results we 
addressed in the present study. Outcomes on cognitive function were also various across 
all studies, and only some have utilized the MMSE (23,30). Nonetheless, it is possible 
to relate the conclusions on the present work to some of these studies, since higher 
content of cocoa in chocolate products relates both to its flavonoid, methylxanthine and 
theobromine concentration.  
There are many possible explanations for the positive effects that have been 
documented and proposed until this day and some of those may still hold theobromine 
at a key spot. 
 
Alternative mechanisms of action 
Despite acting primarily as an adenosine receptor antagonist, theobromine 
participates in three other mechanisms: regulation of intracellular calcium level, 
phosphodiesterase inhibition and modulation of GABAA receptor activity. In fact, high 
doses of methylxanthines, probably achieved through the use of supplements, have 
different actions in other targets, such as interacting with DNA and altering its structure 





Different susceptibility to methylxanthine effects may also be important in this 
context. Unfortunately, current studies have failed to validate clear relationships 
between gene variants, caffeine intake, and phenotypes, information that might help 
solve this question (65).  
One other alternative mechanism of action is the interaction of theobromine with 
A3 receptors. There is no record of theobromine being tested on A3 receptors, but 
similar compounds such as caffeine and theophylline seem to display very low affinity 
for these targets (66). 
It is also interesting to note that antagonists may have different blockade 
potencies for the same type of receptors. This usually depends  on their location in 
specific cells or in specific locations inside the cells (67). One possible explanation for 
theobromine effect is that it acts preferably in specific adenosine receptors, which not 
only might explain its effect on cognition, but also its differential effects compared to 
caffeine (for example, its pro-sleep effect against caffeine’s insomnia effect (68)). 
Finally, the positive interaction with other compounds should not be excluded. 
For example, the interaction with flavonoids is certainly of the most high interest, as 
Jalil et al. recognized when they suggested that there may be direct or indirect 
synergism between flavonoids and methylxanthines (69).  
 
Limitations of this study 
As in other studies, some methodological issues oblige us to be cautious about 
the conclusions we presented in this work. We will discuss some of them and suggest 
improvements for better study modeling in the future. 
Initially, we desired to relate theobromine intake to cognitive decline, but this 
was not possible. The necessity of successive estimates for the calculation of 
theobromine intake (based on the data collected from the FFQ) was perceived to result 
in a probably excessive margin of error. Because of this limitation, we decided to focus 
on chocolate intake, data we could access directly from the FFQ. 
In fact, a common limitation in dietary studies is the error in the estimates of 
nutrients. If the types of certain foods are not specified (i.e. dark chocolate vs milk 
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chocolate),  it is possible to over or underestimate true associations with outcomes (70). 
In the case of chocolate, there is a wide variety on theobromine concentration among 
different types of chocolate and the theobromine/caffeine ratio has also been observed 
to be highly variable: from 1,9 to 10,6 (71). One other limitation was that the FFQ was 
not designed specifically for the assessment of chocolate and theobromine consumption.  
Future studies might need to have a more focused design, with a better FFQ that is able 
to address more precisely and accurately the consumption of cocoa-related products. 
 
 
Table 5) Theobromine content of various products. From (6). 
 
Our results only pointed for a protective effect of chocolate consumption in 
subjects with an average weekly consumption of chocolate lower than one standard 
portion. Despite the relatively high number of participants, is possible that a higher level 
of participation could have contributed for the better understanding of the dose-effect 
relation.  In fact, this is an inherent problem of observational studies of this kind: for 
them to reveal strong conclusions, they require a large number of subjects and a long 
follow-up period.  
MMSE is a well-know and established method to address cognitive functioning. 
However, it might be interesting to explore other ways of assessing this outcome and 
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the effects of the different methylxanthine compounds. For example, 
electrophysiological outcomes such as Cortical Silent Period has been proposed to work 
as surrogate marker of the effect of caffeine in the brain (72). Not only may this 
improved outcome assessment, it may also improve the selection of participants for 
future studies, through the use of specific markers that signal individual susceptibility to 
develop certain pathological processes. 
Finally, it is also important to acknowledge the variety of confounding unknown 
lifestyle factors and the possible presence of substances that alter the effects we have 
proposed to measure. This topic deserves special attention, and must be addressed with 
thorough study design. For example, as alerted in other studies, moderate coffee 
drinking may be related with healthy and social lifestyles that confer part of the 
protective effects or some medical conditions may be overrepresented and negatively 
affect cognitive functions (73). 
 
 
Conclusions and insights for the future 
The present work opens a pathway for more deep and focused research on the 
effects of chocolate consumption and theobromine intake on the prevention of cognitive 
decline. More and better studies for the short and long term effect of chocolate 
consumption are needed.  
Larger-scale, well designed studies that enlarge the body of knowledge available 
are to be promoted. The assessment of different populations and of alternative dosage 
regimens that vary in terms of their flavonoid and methylxanthine content should allow 
for the expansion of the evidence on this topic, such as the possible synergic interaction 
between these two groups of compounds. The development of consensual criteria for 
the definition of outcomes as well as the creation of categories and types of exposure 
might be useful for the better design of future epidemiological studies.  
The findings in the present work should also be confirmed through bigger 
prospective cohort studies, which could detect a possible dose-dependent relation of the 
protective effect of chocolate consumption and/or theobromine. 
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In conclusion, over the last decades our understanding of chocolate effect on 
both physical and mental health has progressed remarkably. Methylxanthines have 
shown to play a key role on the neurocognitive aspects regarding the consumption of 
cocoa-related products. Theobromine, once a widely dismissed compound, has now 
become a potential player on the subject and has deserved a new found interest on its 
neuropharmacological effects. With chocolate being generally the main supplier of 
theobromine to the human diet, there is a clear incentive for the study of alternative way 
of delivering its active compounds and for the thorough research on its effect on the 
prevention of cognitive decline and even the development of neurodegenerative diseases 
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